Cloning of habutobin cDNA and antithrombotic activity of recombinant protein

Masanori Sunagawa1, Mariko Nakamura, Tadayoshi Kosugi

  • 11st Department of Physiology, Unit of Physiological Science, School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa 903-0215, Japan. sunagam@med.u-ryukyu.ac.jp

Insights

Researchers cloned habutobin cDNA from habu snake venom. Recombinant habutobin from a baculoviral system effectively modulated blood clotting and platelet aggregation, showing potential for antithrombotic drug development.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Habutobin is a protein found in Trimeresurus flavoviridis (habu snake) venom.
  • Understanding its structure-function relationship is crucial for potential therapeutic applications.

Purpose of the Study:

  • To clone and express habutobin.
  • To investigate the functional properties of recombinant habutobin, particularly its effects on blood coagulation and platelet aggregation.
  • To assess the utility of different expression systems for producing functional habutobin.

Main Methods:

  • Cloning of habutobin cDNA from Trimeresurus flavoviridis.
  • Expression of recombinant habutobin using bacterial (pET-r-habutobin) and baculoviral (AcNPV-r-habutobin) systems.
  • Purification and refolding of recombinant proteins.
  • Assays for fibrin forming activity and collagen-induced platelet aggregation.

Main Results:

  • Habutobin cDNA was successfully cloned and translated into a 236-amino acid protein (25.7 kDa).
  • Recombinant habutobin was produced and purified via bacterial and baculoviral systems.
  • AcNPV-r-habutobin dose-dependently enhanced fibrin formation and inhibited platelet aggregation.
  • Refolded pET-r-habutobin showed multiple bands, suggesting potential protein processing.

Conclusions:

  • The baculoviral expression system is highly effective for producing functional recombinant habutobin.
  • AcNPV-r-habutobin exhibits significant procoagulant and antiplatelet activities.
  • Further studies on the structure-function relationship of habutobin are warranted for developing novel antithrombotic drugs.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Recombinant DNA01:09

Recombinant DNA

Overview